By blocking SGLT2, empagliflozin reduces renal glucose reabsorption, leading to excretion of glucose in the urine, thus reducing hyperglycemia in patients with T2DM [29]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.